CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

  • ID: 2654490
  • Report
  • Region: United Kingdom, Great Britain
  • 253 pages
  • GlobalData
1 of 5
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

Summary

The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of the UK. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Our team of industry experts.

In 2014, the UK`s population was approximately 64.2 million. The major factors contributing to the growth in the population are increase in net migration and decrease in death rate. The UK policymakers are now presented with the problems of a Eurozone crisis, a declining population of the working age group and an increasing elderly population. The pharmaceutical market in the UK was estimated at $28.8 billion in 2015 and is expected to reach approximately $43.2 billion by 2020 with a projected Compound Annual Growth Rate (CAGR) of 8.4%. The medical devices market size was approximately $14.4 billion in 2015 and is expected to reach approximately $17.9 billion by 2020 with a projected CAGR of 4.5%.

The positive trends in the UK healthcare market can be attributed primarily to -
- Increasing elderly population
- Universal healthcare insurance
- High degree of access to healthcare facilities

Scope

The report provides information on the healthcare, regulatory and reimbursement landscape of the UK. The scope includes -
- Overview of the pharmaceutical and medical devices market of the UK including the market size, market segmentation, key drivers and barriers.
- Profile and SWOT analysis of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Novartis, Roche and Merck. The key players covered for the medical devices market are Essilor International, GlaxoSmithKline, DePuy Companies, Johnson & Johnson and B.Braun.
- Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices.
- A detailed analysis of the political and economic environment of the UK including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
- An overview of the opportunities and challenges for growth that exist in the healthcare market of the UK.

Reasons to buy

The report on the UK comprehensively covers both the pharmaceutical and the medical devices markets of the UK. The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding the trends shaping and driving the healthcare market of the UK.
- Drive revenue by understanding the key trends, and reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the the UK healthcare market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of the various competitors.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
- Identify, understand and capitalize on the opportunities and challenges in the healthcare market of the UK.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 GlobalData Report Guidance

3 Overview of the Pharmaceutical and Medical Device Markets

3.1 Pharmaceutical Market

3.1.1 Market Overview

3.1.2 Pharmaceutical Exports and Imports

3.1.3 Supply Channels

3.1.4 Market Segments

3.1.5 Major Therapeutic Areas

3.1.6 Major Companies

3.2 Medical Device Market

3.2.1 Market Overview

3.2.2 Overview of Top Five Segments

3.2.3 Diagnostic market

3.2.4 Major Players

3.3 Market Drivers and Barriers

3.3.1 Drivers

3.3.2 Barriers

4 Market Access

4.1 Reimbursement and Payer Landscape

4.1.1 Overview of Healthcare System

4.1.2 Reimbursement Process

4.1.3 Overview of Insurance Providers

4.1.4 Patient Share in Healthcare Spending

4.1.5 Drug Price Change

4.1.6 Pricing Policies

4.2 Regulatory Landscape

4.2.1 Overview of Regulatory Agencies

4.2.2 Market Authorization Procedure for Pharmaceutical Products

4.2.3 New Medical Device Approval Process

4.2.4 Licensing Process for Pharmaceutical Manufacturing

4.2.5 Intellectual Property Rights

4.2.6 Clinical Trial Regulations

4.2.7 Pharmaceutical Advertising Regulations

4.2.8 Pharmacy Regulations

4.2.9 Labeling and Packaging Regulations

5 Country Analysis

5.1 Political Environment

5.1.1 Political Structure

5.1.2 Analysis of the Current Political Environment

5.1.3 Healthcare Policy Initiatives

5.2 Economic Landscape

5.3 Economic Indicators

5.3.1 Gross Domestic Product

5.3.2 Gross National Income

5.3.3 Inflation

5.3.4 Currency Exchange Rate

5.3.5 Foreign Direct Investment

5.3.6 Foreign Exchange Reserves

5.3.7 Trade Balance

5.3.8 Government Structural Balance

5.3.9 General Government Gross Debt

5.3.10 External Debt

5.3.11 Major Industries

5.4 Demographics

5.4.1 Population

5.4.2 Education and Literacy

5.4.3 Employment

5.4.4 Disease Burden

5.5 Healthcare Infrastructure

5.5.1 Healthcare Facilities

5.5.2 Healthcare Parameters

5.5.3 Environmental Health

5.5.4 Healthcare Personnel

5.6 Healthcare Expenditure

5.6.1 Overview

5.6.2 Components of Healthcare Spending

5.6.3 Public and Private Sector Share

5.6.4 Spending in Pharmaceutical R&D

5.7 Trade Associations

5.7.1 Association of the British Pharmaceutical Industry (ABPI)

5.7.2 British In Vitro Diagnostics Association (BIVDA)

5.7.3 National Pharmacy Association (NPA)

5.7.4 Association of British Healthcare Industries (ABHI)

5.7.5 British Generic Manufacturers Association (BGMA)

5.8 Trade Fairs

6 Opportunities and Challenges

6.1 Opportunities

6.2 Challenges

7 Appendix

7.1 Abbreviations

7.2 Bibliography

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasts

7.3.4 Expert Panel

7.4 Disclaimer

1.1 List of Tables

Table 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015

Table 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020

Table 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015

Table 4: Major Therapeutic Areas, UK, Prescribing cost ($bn) , 2015

Table 5: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015

Table 6: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015

Table 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Problems ($bn), 2008-2015

Table 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Problems ($bn), 2008-2015

Table 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Problems ($bn), 2008-2015

Table 10: Pharmaceutical Market, Pfizer, Global, Major Products by Revenue ($bn) and Annual Growth (%), Revenue, 2014

Table 11: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2015

Table 12: Pharmaceutical Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014

Table 13: Pharmaceutical Market, GlaxoSmithKline, Global, Late-Stage Pipeline, 2015

Table 14: Pharmaceutical Market, Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013

Table 15: Pharmaceutical Market, Novartis, Global, Planned Filings, 2016-2019

Table 16: Pharmaceutical Market, Roche, Global, Major Products, Revenue ($m) and Annual Growth (%), 2013

Table 17: Pharmaceutical Market, Roche, Global, Late-stage Pipeline, 2013

Table 18: Pharmaceutical Market, Merck, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013

Table 19: Pharmaceutical Market, Merck, Global, Late-Stage Pipeline, 2014

Table 20: Medical Device Market, UK, Revenue ($bn), 2008-2015

Table 21: Medical Device Market, UK, Revenue ($bn), 2016-2020

Table 22: Medical Device Market, UK, Revenue ($bn), 2014

Table 23: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015

Table 24: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014

Table 25: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015

Table 26: Medical Device Market, UK, Ophthalmic Devices, Market Share (%), 2014

Table 27: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015

Table 28: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012

Table 29: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015

Table 30: Medical Device Market, UK, Cardiovascular Device Market, Market Share, 2012

Table 31: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015

Table 32: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012

Table 33: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015

Table 34: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020

Table 35: Medical Device Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014

Table 36: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015

Table 37: Market Access, UK, Drug Price Change (%), 2008-2015

Table 38: Market Access, UK, Schedule of Patent Fees, 2015

Table 39: Market Access, UK, Schedule of Trademark Fees, 2015

Table 40: Market Access, UK, Clinical Trials Application Fees, 2015

Table 41: Market Access, UK, Clinical trials application fees, 2015

Table 42: Economic Indicators, UK, GDP per Capita ($), 2008-2015

Table 43: Economic Indicators, UK, GDP per Capita ($), 2016-2020

Table 44: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015

Table 45: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020

Table 46: Economic Indicators, UK, National Income ($ tn), 2008-2014

Table 47: Economic Indicators, UK, Average Consumer Price Index, 2008-2015

Table 48: Economic Indicators, UK Average Consumer Price Index, 2016-2020

Table 49: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014

Table 50: Economic Indicators, UK, Currency Exchange Rate (£ to $), 2008-2014

Table 51: Economic Indicators, UK, FDI ($bn), 2008-2014

Table 52: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014

Table 53: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014

Table 54: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014

Table 55: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014

Table 56: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015

Table 57: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020

Table 58: Economic Indicators, UK, External Debt ($tr), 2008-2014

Table 59: Economic Indicators, UK, Major Industries, National Income by Industry ($bn), 2013

Table 60: Demographics, UK, Population (million), 2008-2014

Table 61: Demographics, UK, Population Forecast (million), 2016-2020

Table 62: Demographics, UK, Urban and Rural Population (%), 2008-2014

Table 63: Demographics, UK, Population Distribution by Age Group (%), 2008-2015

Table 64: Demographics, UK, Population Distribution by Age Group (%), 2016-2020

Table 65: Demographics, UK, Births (per 1,000 Population), 2008-2014

Table 66: Demographics, UK, Mortality (per 1,000 Population), 2008-2014

Table 67: Demographics, UK, Major Causes of Mortality (%), 2014

Table 68: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014

Table 69: Demographics, UK, Immunization Rate (%), 2013

Table 70: Demographics, UK, Major Causes of Male Mortality (‘000), 2014

Table 71: Demographics, UK, Major Causes of Female Mortality (‘000), 2014

Table 72: Demographics, UK, Gender Ratio (M/F), 2008-2014

Table 73: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014

Table 74: Demographics, UK, Gross Enrollment (%), 2008-2015

Table 75: Demographics, UK, Unemployment Rate (%), 2008-2014

Table 76: Demographics, UK, Disease Burden, DALYs (per 100,000 population), 2013

Table 77: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014

Table 78: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014

Table 79: Healthcare Infrastructure, UK, Hospital Beds (per 1,000 Population), 2008-2014

Table 80: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014

Table 81: Healthcare Infrastructure, UK, CO2 emissions (million), 2008-2014

Table 82: Healthcare Infrastructure, UK, CH4 emissions (million tons), 2008-2014

Table 83: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014

Table 84: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014

Table 85: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014

Table 86: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014

Table 87: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014

Table 88: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013

Table 89: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014

Table 90: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014

Table 91: Major Healthcare Trade Fairs, UK, 2016

1.2 List of Figures

Figure 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015

Figure 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020

Figure 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015

Figure 4: Pharmaceutical Market, UK, Supply Channels, 2014

Figure 5: Pharmaceutical Market, UK, Generic Launch, 2013

Figure 6: Major Therapeutic Areas, UK, Prescribing Cost ($bn), 2015

Figure 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015

Figure 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015

Figure 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Issues ($bn), 2008-2015

Figure 10: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Issues ($bn), 2008-2015

Figure 11: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Issues ($bn), 2008-2015

Figure 12: Medical Device Market, UK, Revenue ($bn), 2008-2015

Figure 13: Medical Device Market, UK, Revenue ($bn), 2016-2020

Figure 14: Medical Device Market, UK, Revenue ($bn), 2014

Figure 15: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015

Figure 16: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014

Figure 17: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015

Figure 18: Medical Device Market, UK, Ophthalmic Devices Market Share (%), 2012

Figure 19: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015

Figure 20: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012

Figure 21: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015

Figure 22: Medical Device Market, UK, Cardiovascular Device Market, Share (%), 2012

Figure 23: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015

Figure 24: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012

Figure 25: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015

Figure 26: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020

Figure 27: Healthcare Market, UK, Drivers and Barriers, 2015

Figure 28: Healthcare System, UK, 2015

Figure 29: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015

Figure 30: Market Access, UK, Drug Price Change (%), 2008-2015

Figure 31 Healthcare System, UK, MHRA Structure, 2015

Figure 32: Healthcare System, UK, National Procedure for Market Authorization, 2015

Figure 33: Healthcare System, EU, Centralized Procedure, Pre-Submission, 2015

Figure 34: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Pre-Opinion Phase, 2015

Figure 35: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Post-opinion Phase, 2015

Figure 36: Healthcare System, EU, Decentralized Procedure, 2015

Figure 37: Healthcare System, EU, Mutual Recognition Procedure, 2015

Figure 38: Healthcare System, EU, Conformity Assessment of Class I Medical Devices, 2013

Figure 39: Healthcare System, EU, Conformity Assessment of Class IIa Medical Devices, 2013

Figure 40: Healthcare System, EU, Conformity Assessment of Class IIb Medical Devices, 2013

Figure 41: Healthcare System, EU, Conformity Assessment of Class III Medical Devices, 2013

Figure 42: Healthcare System, UK, Patent Approval Process, 2015

Figure 43: Healthcare System, UK, Clinical Trial Regulation Process for Medicines, 2015

Figure 44: Healthcare System, UK, Clinical Trial Regulation Process for Medical Devices, 2013

Figure 45: Economic Indicators, UK, GDP per Capita ($), 2008-2015

Figure 46: Economic Indicators, UK, GDP per Capita ($), 2016-2020

Figure 47: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015

Figure 48: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020

Figure 49: Economic Indicators, UK, National Income ($tn), 2008-2014

Figure 50: Economic Indicators, UK, Average Consumer Price Index, 2008-2015

Figure 51: Economic Indicators, UK, Average Consumer Price Index, 2016-2020

Figure 52: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014

Figure 53: Economic Indicators, UK, Currency Exchange Rate ($ to £), 2008-2014

Figure 54: Economic Indicators, UK, FDI ($bn), 2008-2014

Figure 55: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014

Figure 56: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014

Figure 57: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014

Figure 58: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014

Figure 59: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015

Figure 60: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020

Figure 61: Economic Indicators, UK, External Debt ($tn), 2008-2014

Figure 62: Economic Indicators, UK, Major Industries, Gross Value Added ($bn), 2013

Figure 63: Demographics, UK, Population (million), 2008-2015

Figure 64: Demographics, UK, Population (million), 2016-2020

Figure 65: Demographics, UK, Urban and Rural Population (%), 2008-2014

Figure 66: Demographics, UK, Population Distribution by Age Group (%), 2008-2015

Figure 67: Demographics, UK, Population Distribution by Age Group (%), 2016-2020

Figure 68: Demographics, UK, Births (per 1,000 Population), 2008-2014

Figure 69: Demographics, UK, Mortality (per 1,000 Population), 2008-2014

Figure 70: Demographics, UK, Major Causes of Mortality (%), 2014

Figure 71: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014

Figure 72: Demographics, UK, Immunization Rate (%), 2013

Figure 73: Demographics, UK, Major Causes of Male Mortality (‘000), 2014

Figure 74: Demographics, UK, Major Causes of Female Mortality (‘000), 2014

Figure 75: Demographics, UK, Gender Ratio (M/F), 2008-2014

Figure 76: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014

Figure 77: Demographics, UK, Gross Enrollment (%), 2008-2015

Figure 78: Demographics, UK, Unemployment Rate (%), 2008-2014

Figure 79: Demographics, UK Disease Burden, DALYs (per 100,000 population), 2013

Figure 80: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014

Figure 81: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014

Figure 82: Healthcare Infrastructure, UK, Hospital Beds (Per 1,000 Population), 2008-2014

Figure 83: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014

Figure 84: Healthcare Infrastructure, UK, CO2 emissions (million tons), 2008-2014

Figure 85: Healthcare Infrastructure, UK, CH4 emissions (million tons)2008-2014

Figure 86: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014

Figure 87: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014

Figure 88: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014

Figure 89: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014

Figure 90: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014

Figure 91: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013

Figure 92: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014

Figure 93: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014

Figure 94: Healthcare Market, UK, Opportunities and Challenges, 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
A growing disease burden, universal healthcare coverage, and good access to healthcare facilities provide the necessary momentum for the growth of the UK healthcare market; but increasing use of generics and government cost-cutting measures to reduce expenditure are restricting growth.

The pharmaceutical market in the UK was worth approximately $24 billion in 2012 and is projected to reach approximately $31.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 3.5% (OECD, 2011). The segments that dominated the market in 2012 were Central Nervous System (CNS) drugs, cardiovascular drugs, and respiratory system drugs. The UK is one of the most profitable healthcare markets among the European Union (EU) member states.

The prevalence of hypertension has increased from 7.4 million in 2010–2011 to 7.6 million in 2011–2012. The prevalence of depression in people above 18 years of age increased from 4.8 million in 2010–2011 to 5.1 million in 2011–2012. In 2012, the prevalence of diabetes in England increased by 4.5% from 2011. The government has allocated funds to encourage R&D and has implemented campaigns to enhance the prevention and treatment of chronic diseases such as cancer and diabetes.

The UK provides public healthcare to all citizens, approximately 63.2 million people. The National Health Service (NHS) is responsible for the public healthcare sector of the UK. The NHS is the one of the world’s largest healthcare system and provides a wide range of healthcare services to the entire population, such as routine treatments for long-term conditions, transplants, emergency treatment, antenatal screening, and end-of-life care, but charges for dental and optical services. Healthcare coverage is free at the point of need, and funding comes from taxation and is granted to the Department of Health (DH) (NHS, 2013a).

Increasing generic substitution and cost-cutting measures adopted by the government and the NHS have on the other hand had a negative impact on market growth. Price cuts have led to market decline. The UK’s government introduced price cuts on branded medicines of 3.9% in 2009 and 1.9% in 2010 to reduce NHS expenditure (DH, 2008). In 2013, the DH announced plans to cut drug prices by 10–20% on approximately 10% of branded medicines not covered by the voluntary Pharmaceutical Price Regulation Scheme (PPRS) (DH, 2013). Generic substitution by pharmacists was implemented by the NHS in 2009 and has reduced the overall value of the pharmaceutical market.

The medical device market was worth approximately $12 billion in 2012, placing the UK fourth in Europe after Germany, France, and Italy. The market is projected to reach approximately $17.5 billion by 2020 at a CAGR of 4.8%.

In 2012, the major segments of the medical device market in terms of share were ophthalmic devices ($1.4 billion), orthopedic devices ($1.4 billion), wound care management ($1.1 billion), cardiovascular devices ($1.1 billion) and drug delivery devices ($1 billion).

With the availability of reimbursement, advances in medical technology, and growing disease awareness enabling early diagnosis, the medical device market in the UK is expected to grow significantly in the future.

Directive 2007/47/EC amended both the Medical Devices and Active Implantable Medical Devices Directives, and a revision of this Directive came into force in 2010 in order to improve and strengthen regulations.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll